Skip to main
HCAT

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 11%
Hold 78%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst is a leading player in the healthcare analytics market, with its integrated data analytics solution and high-end professional services setting it apart from competitors. Despite current economic uncertainty and budget pressures in the healthcare sector, the company's successful ramp of Tech-Enabled Managed Services contracts and competitive positioning present a favorable outlook for future growth and profitability. The company's focus on migrating clients to its more robust and flexible Ignite platform also bodes well for sustainable growth and margin expansion in the long term.

Bears say

Health Catalyst is facing challenges with customer retention and potential downsells due to the transition from DOS to Ignite, resulting in a decrease in ARR and potential churn in the coming years. However, the company has shown some success with new customer acquisitions and has potential in its VitalWare application assets, which could generate significant revenue and profit. But with a negative outlook on the company's potential risks and challenges, it is difficult to determine the likelihood of long-term success.

HCAT has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 11% recommend Buy, 78% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Hold based on their latest research and market trends.

According to 9 analysts, HCAT has a Hold consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.